Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for Lucid-MS, allowing the company to proceed with a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis. The announcement signals a critical step forward for a drug that takes a fundamentally different approach to treating MS, one that could reshape how the disease is managed if clinical results confirm preclinical findings.
Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2, or PAD2. Unlike currently approved MS therapies that primarily suppress the immune system to reduce relapses, Lucid-MS is designed to target demyelination directly. Myelin degradation is the underlying mechanism of multiple sclerosis, and the drug has been shown in preclinical models to both prevent and reverse myelin degradation. This mechanism of action positions Lucid-MS as a potential disease-modifying therapy that addresses the root cause of disability progression rather than just managing symptoms.
The significance of the FDA clearance lies in the broader implications for MS treatment. If Lucid-MS succeeds in phase 2, it could offer a new therapeutic category for patients who do not respond adequately to existing immune-modulating drugs. The trial will evaluate whether the drug can safely and effectively slow or reverse demyelination in humans, a milestone that would validate the PAD2 inhibition strategy and open the door to applications in other neurodegenerative conditions.
Quantum BioPharma's research collaboration with Massachusetts General Hospital and Harvard Medical School further strengthens its scientific foundation. The collaboration involves the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a method to visualize and measure demyelination. This imaging tool could provide objective biomarkers for treatment response, enhancing the design and interpretation of the phase 2 trial. The ability to directly observe myelin repair in patients would be a significant advance for MS research and could accelerate drug development across the field.
The company's pipeline also includes other assets, such as UNBUZZD, an over-the-counter product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake as of March 31, 2026, along with royalty rights. However, the primary near-term value driver remains Lucid-MS, and the phase 2 trial will be closely watched by investors and clinicians alike.
Quantum BioPharma operates through its wholly owned subsidiary, Lucid Psycheceuticals Inc., which is focused on the research and development of Lucid-MS. The company is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
For a full view of the press release, visit https://ibn.fm/lCey9.
